GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. Buxton, M., Alexander, B., Berry, D. A., Cavenee, W. K., Colman, H., De Groot, J., Ellingson, B. M., Gordon, G. B., Khasraw, M., Lassman, A. B., Li, W., Lim, M., Mellinghoff, I. K., Perry, J. R., Sulman, E. P., Tanner, K., Weller, M., Wen, P. Y., Yung, W., Cloughesy, T., GBM AGILE Investigators LIPPINCOTT WILLIAMS & WILKINS. 2020

View details for Web of Science ID 000560368309059